← Back to patent-cliff list
JIN-A02
Tier C — Watch / tradeJIN-A02
J INTS BIO Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR C797S
Indications (approved)：Non-small cell lung cancer, 转移性上皮癌
Regional status
US
Phase II
2023-07-30
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of JIN-A02?
Approved indications include: Non-small cell lung cancer, 转移性上皮癌.
When does the JIN-A02 patent expire?
No public expiry year is available for JIN-A02 yet; this page updates once verified.
How do I get a quote for JIN-A02 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02